Illinois Municipal Retirement Fund trimmed its position in ResMed Inc. (NYSE:RMD – Free Report) by 13.4% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 15,689 shares of the medical equipment provider’s stock after selling 2,437 shares during the quarter. Illinois Municipal Retirement Fund’s holdings in ResMed were worth $3,469,000 as of its most recent SEC filing.
Other institutional investors and hedge funds also recently bought and sold shares of the company. BlackRock Inc. purchased a new stake in shares of ResMed in the 2nd quarter valued at approximately $2,400,375,000. Bank of New York Mellon Corp acquired a new stake in shares of ResMed during the 2nd quarter worth approximately $818,030,000. Deutsche Bank AG acquired a new stake in shares of ResMed during the 2nd quarter worth approximately $257,692,000. Legal & General Group Plc purchased a new stake in shares of ResMed during the 2nd quarter valued at approximately $183,697,000. Finally, Bank of America Corp DE purchased a new stake in shares of ResMed during the 2nd quarter valued at approximately $151,115,000. 54.98% of the stock is currently owned by institutional investors and hedge funds.
Insider Buying and Selling
In related news, Director Peter Farrell sold 970 shares of ResMed stock in a transaction that occurred on Wednesday, September 2nd. The shares were sold at an average price of $234.73, for a total value of $227,688.10. Following the completion of the sale, the director owned 51,803 shares in the company, valued at approximately $12,159,718.19. This trade represents a 1.84% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, General Counsel Michael Rider sold 400 shares of ResMed stock in a transaction that occurred on Friday, October 23rd. The shares were sold at an average price of $255.00, for a total transaction of $102,000.00. Following the completion of the sale, the general counsel owned 12,318 shares of the company’s stock, valued at $3,141,090. This trade represents a 3.15% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 16,345 shares of company stock valued at $3,744,602. Company insiders own 0.58% of the company’s stock.
ResMed Trading Up 0.3%
RMD stock traded up $0.68 during mid-day trading on Friday, hitting $239.57. 853,163 shares of the company were exchanged, compared to its average volume of 1,510,457. The company has a quick ratio of 1.88, a current ratio of 2.65 and a debt-to-equity ratio of 0.04. The firm has a market capitalization of $33.70 billion, a P/E ratio of 21.82, a PEG ratio of 1.45 and a beta of 0.77. The business has a fifty day simple moving average of $232.20 and a 200-day simple moving average of $224.41. ResMed Inc. has a 12-month low of $180.26 and a 12-month high of $277.67.
ResMed (NYSE:RMD – Get Free Report) last announced its quarterly earnings results on Thursday, October 29th. The medical equipment provider reported $2.91 earnings per share for the quarter, beating analysts’ consensus estimates of $2.67 by $0.24. The business had revenue of $1.41 billion during the quarter, compared to analysts’ expectations of $1.39 billion. ResMed had a net margin of 27.79% and a return on equity of 26.42%. The business’s revenue for the quarter was up 5.9% on a year-over-year basis. During the same period last year, the business earned $2.55 earnings per share. On average, equities research analysts predict that ResMed Inc. will post 12.14 earnings per share for the current fiscal year.
ResMed Announces Dividend
The business also recently disclosed a quarterly dividend, which will be paid on Thursday, December 17th. Investors of record on Thursday, November 12th will be given a dividend of $0.66 per share. The ex-dividend date of this dividend is Thursday, November 12th. This represents a $2.64 dividend on an annualized basis and a dividend yield of 1.1%. ResMed’s dividend payout ratio (DPR) is presently 24.04%.
Analyst Upgrades and Downgrades
RMD has been the topic of a number of recent analyst reports. Canaccord Genuity Group cut ResMed from a “buy” rating to a “hold” rating in a report on Monday, November 2nd. UBS Group reissued a “buy” rating and set a $300.00 target price on shares of ResMed in a research note on Tuesday, July 21st. Wells Fargo & Company raised their target price on ResMed from $215.00 to $250.00 and gave the stock an “equal weight” rating in a research note on Friday, October 30th. Royal Bank Of Canada lifted their target price on ResMed from $262.00 to $288.00 and gave the company an “outperform” rating in a research report on Friday, October 30th. Finally, Weiss Ratings raised ResMed from a “hold (c)” rating to a “hold (c+)” rating in a research note on Thursday, October 8th. Seven equities research analysts have rated the stock with a Buy rating and eleven have assigned a Hold rating to the stock. According to data from MarketBeat, ResMed presently has a consensus rating of “Hold” and a consensus price target of $253.69.
Get Our Latest Stock Analysis on ResMed
ResMed Profile
ResMed is a medical technology company that develops products and software for people with sleep apnea, chronic obstructive pulmonary disease and other respiratory conditions. Its devices include continuous positive airway pressure (CPAP) and bilevel machines, ventilators and related masks and accessories. The company also provides cloud-connected software for managing sleep and respiratory care, along with digital tools used by home medical equipment providers and post-acute care organizations.
Featured Articles
- Five stocks we like better than ResMed
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
- Is It Too Late to Buy the Dip? 3 Corners of the Market Still Offering Real Value
Want to see what other hedge funds are holding RMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ResMed Inc. (NYSE:RMD – Free Report).
Receive News & Ratings for ResMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ResMed and related companies with MarketBeat.com's FREE daily email newsletter.
